RE:RE:RE:RE:Pfizer partners with startup Flagship valued at US$7 BillionPartnerships are formed around early stage companies. ONCY is a late stage Phase 3-ready bio-platform company whose platform addresses multiple cancers with unmet treatment needs, like the kind of potential high-value assets that Big Pharma companies are seeking to acquire given their need to address their looming patent cliffs and replenishment of their product portfolios, that are specifically targeting biologicals in the immuno-oncology market space.